MedTrace Logo

Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation

NCT01841086 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-04-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics of sarpogrelate controlled-release formulation (CR) in comparison to immediate-release formulation (IR) and Food effect on the pharmacokinetics of sarpogrelate CR.

Conditions

  • Healthy

Interventions

DRUG

Anplag

Sarpogrelate HCl 300mg once a day or 100mg three times a day

DRUG

UI03SPG300CT

Sarpogrelate HCl 300mg once a day or 100mg three times a day

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Principal Investigators

  • Wooseong Huh, M.D., Ph.D. · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2011-11-30
Completion
2011-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01841086 on ClinicalTrials.gov